Clearance of liposomal gadolinium

in vivo decomplexation.

Evan C Unger, T. A. Fritz, C. Tilcock, T. E. New

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The contrast agents gadolinium-DTPA (diethylenetriaminepentaacetic acid), Gd-DOTA (tetraazacyclododecanetetraacetic acid), and Gd-HP-DO3A (1,4,7-tris[carboxymethyl]-10-[2' hydroxypropyl]-1,4,7,10-tetraazacyclododecane) are used in humans as extracellular contrast agents. Although free Gd+ ion is toxic, the intact Gd3+ complexes are rapidly excreted and are relatively nontoxic. Decomplexation with release of free gadolinium is a relevant clinical concern in patients with altered renal clearance. Blood pool contrast agents currently under development may have longer clearance half-lives and be more prone to decomplexation. The present study was designed to evaluate the clearance of liposomally encapsulated Gd3+ complexes (DTPA, DOTA, and HP-DO3A). The macrocyclic compounds had more rapid and complete clearance than DTPA (P less than .05). Parallel studies with carbon-14 and Gd-153-labeled complexes showed significant differences (P less than .05) in the amount of these isotopes retained in the heart, kidney, lungs, and spleen, providing strong supportive evidence for in vivo decomplexation.

Original languageEnglish (US)
Pages (from-to)689-693
Number of pages5
JournalJournal of Magnetic Resonance Imaging
Volume1
Issue number6
StatePublished - Nov 1991

Fingerprint

Gadolinium
Contrast Media
Pentetic Acid
Macrocyclic Compounds
Kidney
Gadolinium DTPA
Poisons
Isotopes
Carbon
Spleen
Ions
Lung
Acids

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Clearance of liposomal gadolinium : in vivo decomplexation. / Unger, Evan C; Fritz, T. A.; Tilcock, C.; New, T. E.

In: Journal of Magnetic Resonance Imaging, Vol. 1, No. 6, 11.1991, p. 689-693.

Research output: Contribution to journalArticle

Unger, EC, Fritz, TA, Tilcock, C & New, TE 1991, 'Clearance of liposomal gadolinium: in vivo decomplexation.', Journal of Magnetic Resonance Imaging, vol. 1, no. 6, pp. 689-693.
Unger, Evan C ; Fritz, T. A. ; Tilcock, C. ; New, T. E. / Clearance of liposomal gadolinium : in vivo decomplexation. In: Journal of Magnetic Resonance Imaging. 1991 ; Vol. 1, No. 6. pp. 689-693.
@article{189d6255fe5641d1b93aa1e18d837300,
title = "Clearance of liposomal gadolinium: in vivo decomplexation.",
abstract = "The contrast agents gadolinium-DTPA (diethylenetriaminepentaacetic acid), Gd-DOTA (tetraazacyclododecanetetraacetic acid), and Gd-HP-DO3A (1,4,7-tris[carboxymethyl]-10-[2' hydroxypropyl]-1,4,7,10-tetraazacyclododecane) are used in humans as extracellular contrast agents. Although free Gd+ ion is toxic, the intact Gd3+ complexes are rapidly excreted and are relatively nontoxic. Decomplexation with release of free gadolinium is a relevant clinical concern in patients with altered renal clearance. Blood pool contrast agents currently under development may have longer clearance half-lives and be more prone to decomplexation. The present study was designed to evaluate the clearance of liposomally encapsulated Gd3+ complexes (DTPA, DOTA, and HP-DO3A). The macrocyclic compounds had more rapid and complete clearance than DTPA (P less than .05). Parallel studies with carbon-14 and Gd-153-labeled complexes showed significant differences (P less than .05) in the amount of these isotopes retained in the heart, kidney, lungs, and spleen, providing strong supportive evidence for in vivo decomplexation.",
author = "Unger, {Evan C} and Fritz, {T. A.} and C. Tilcock and New, {T. E.}",
year = "1991",
month = "11",
language = "English (US)",
volume = "1",
pages = "689--693",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Clearance of liposomal gadolinium

T2 - in vivo decomplexation.

AU - Unger, Evan C

AU - Fritz, T. A.

AU - Tilcock, C.

AU - New, T. E.

PY - 1991/11

Y1 - 1991/11

N2 - The contrast agents gadolinium-DTPA (diethylenetriaminepentaacetic acid), Gd-DOTA (tetraazacyclododecanetetraacetic acid), and Gd-HP-DO3A (1,4,7-tris[carboxymethyl]-10-[2' hydroxypropyl]-1,4,7,10-tetraazacyclododecane) are used in humans as extracellular contrast agents. Although free Gd+ ion is toxic, the intact Gd3+ complexes are rapidly excreted and are relatively nontoxic. Decomplexation with release of free gadolinium is a relevant clinical concern in patients with altered renal clearance. Blood pool contrast agents currently under development may have longer clearance half-lives and be more prone to decomplexation. The present study was designed to evaluate the clearance of liposomally encapsulated Gd3+ complexes (DTPA, DOTA, and HP-DO3A). The macrocyclic compounds had more rapid and complete clearance than DTPA (P less than .05). Parallel studies with carbon-14 and Gd-153-labeled complexes showed significant differences (P less than .05) in the amount of these isotopes retained in the heart, kidney, lungs, and spleen, providing strong supportive evidence for in vivo decomplexation.

AB - The contrast agents gadolinium-DTPA (diethylenetriaminepentaacetic acid), Gd-DOTA (tetraazacyclododecanetetraacetic acid), and Gd-HP-DO3A (1,4,7-tris[carboxymethyl]-10-[2' hydroxypropyl]-1,4,7,10-tetraazacyclododecane) are used in humans as extracellular contrast agents. Although free Gd+ ion is toxic, the intact Gd3+ complexes are rapidly excreted and are relatively nontoxic. Decomplexation with release of free gadolinium is a relevant clinical concern in patients with altered renal clearance. Blood pool contrast agents currently under development may have longer clearance half-lives and be more prone to decomplexation. The present study was designed to evaluate the clearance of liposomally encapsulated Gd3+ complexes (DTPA, DOTA, and HP-DO3A). The macrocyclic compounds had more rapid and complete clearance than DTPA (P less than .05). Parallel studies with carbon-14 and Gd-153-labeled complexes showed significant differences (P less than .05) in the amount of these isotopes retained in the heart, kidney, lungs, and spleen, providing strong supportive evidence for in vivo decomplexation.

UR - http://www.scopus.com/inward/record.url?scp=0026250577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026250577&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 689

EP - 693

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 6

ER -